SLC5A2 and Alzheimer disease: Their results indicated that EMP therapy improved cognitive impairments in APP/PS1xdb/db mice by reducing bleeding, microglial loads, and adverse neurovascular alterations, which shows that there is evidence for the ability of SGLT-2 inhibitors to modulate inflammation-relevant microglia in AD brains.